<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Daniel Carpenter</style></author><author><style face="normal" font="default" size="100%">Evan James Zucker</style></author><author><style face="normal" font="default" size="100%">Jerry Avorn</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">“Drug Review Deadlines and Subsequent Safety Problems”</style></title><secondary-title><style face="normal" font="default" size="100%">New England Journal of Medicine  </style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2008</style></year></dates><volume><style face="normal" font="default" size="100%">358</style></volume><pages><style face="normal" font="default" size="100%">1354-61</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><issue><style face="normal" font="default" size="100%">13</style></issue><notes><style face="normal" font="default" size="100%">Errata and Corrected Estimates: New England Journal of Medicine 359 (1) (July 3, 2008) 95-98. 
Initial results presented at the annual meeting of the American Association for the Advancement of Science (AAAS), St. Louis, Missouri, April 2005; also presented at the FDA-NIH Management Conference, College Park, Maryland, May 2005. 
Selected as one of the 25 most influential research articles of 2008; Robert Wood Johnson Foundation.</style></notes></record></records></xml>